期刊
CANCER BIOLOGY & THERAPY
卷 3, 期 7, 页码 612-613出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.3.7.931
关键词
histone deacetylase inhibitors; phenylbutyrate; cutaneous radiation syndrome; radiotherapy
类别
Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deaceyase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据